Co-ordinated isolation of CD8⁺ and CD4⁺ T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy

References

• Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202: 673–85.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Wills MR, Sissons JG, Carmichael AJ. Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev. 2003;17: 259–64.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4: 725–38.
   PubMed Web of Science ®Google Scholar
• Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther. 2003;98: 269–97.
   PubMed Web of Science ®Google Scholar
• Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol. 2004;65: 403–9.
   PubMedGoogle Scholar
• Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, . Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101: 407–14.
   PubMed Web of Science ®Google Scholar
• Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, . Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by inter-feron-gamma enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood. 2002;99: 3830–7.
   PubMed Web of Science ®Google Scholar
• Foster AE, Gottlieb DJ, Sartor M, Hertzberg MS, Bradstock KF. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8: 501–11.
   PubMedGoogle Scholar
• Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, Locatelli F. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood. 2006;108: 1406–12.
   PubMed Web of Science ®Google Scholar
• Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38: 687–92.
   PubMedGoogle Scholar
• Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93: 248–56.
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, . Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038–44.
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, . Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202: 379–86.
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, . Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12: 1160–6.
   PubMed Web of Science ®Google Scholar
• Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, . Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13: 707–14.
   PubMed Web of Science ®Google Scholar
• Meij P, Zandvliet ML, Van der Heiden PLJ, Jedema I, Van Egmond HM, Cox LMP, . Generation and administration of CMV pp65-specific donor T-cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation. EBMT [Abstract] www.congrex.ch/ebmt2007. 33rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Lyon, France. 2007.
   Google Scholar
• Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, . Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112: 3974–81.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, . Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362: 1375–7.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Mackinnon S. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Hum Immunol. 2004;65: 550–7.
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, . Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99: 3916–22.
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, . Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106: 4397–406.
   PubMed Web of Science ®Google Scholar
• Rentenaar RJ, Gamadia LE, van DerHoek N, van Diepen FN, Boom R, Weel JF, . Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest. 2000;105: 541–8.
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003; 101:2686–92.
   PubMed Web of Science ®Google Scholar
• Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, . Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med. 2006;203: 2865–77.
   PubMed Web of Science ®Google Scholar
• Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, . Ex vivo profiling of CD8+T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 2003;77: 5226–40.
   PubMed Web of Science ®Google Scholar
• Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, . Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005; 201:1999–2010.
   PubMedGoogle Scholar
• Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, . Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274: 94–6.
   PubMed Web of Science ®Google Scholar
• Yao J, Bechter C, Wiesneth M, Harter G, Gotz M, Germeroth L, . Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis. 2008;46:e96–105.
   PubMed Web of Science ®Google Scholar
• Zandvliet ML, Falkenburg JH, Jedema I, Willemze R, Guchelaar HJ, Meij P. Detailed analysis of IFNγ response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy. J Immunother. 2009;32: 513–23.
   PubMedGoogle Scholar
• Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008;40: 63–7.
   PubMed Web of Science ®Google Scholar
• Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C, . Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000;30: 1676–82.
   PubMed Web of Science ®Google Scholar
• Kiecker F, Streitz M, Ay B, Cherepnev G, Volk HD, Volkmer-Engert R, . Analysis of antigen-specific T-cell responses with synthetic peptides: what kind of peptide for which purpose? Hum Immunol. 2004;65:523–36.
   PubMedGoogle Scholar
• Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005;105: 2793–801.
   PubMedGoogle Scholar
• Faber LM, Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992;176: 1283–9.
   PubMed Web of Science ®Google Scholar
• Kondo E, Akatsuka Y, Kuzushima K, Tsujimura K, Asakura S, Tajima K, . Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood. 2004;103: 630–8.
   PubMedGoogle Scholar
• Harcourt GC, Scriba TJ, Semmo N, Bounds S, Taylor E, Klenerman P. Identification of key peptide-specific CD4+ T-cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin Exp Immunol. 2006;146: 203–10.
   PubMedGoogle Scholar
• Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, . Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274: 94–6.
   PubMed Web of Science ®Google Scholar
• Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103: 2677–82.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Tato CM, Stumhofer JS, Yao Z, Cui YK, Hennighausen L, . Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med. 2007;204: 65–71.
   PubMedGoogle Scholar
• Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 1997;15: 821–50.
   PubMed Web of Science ®Google Scholar
• Zandvliet ML, Falkenburg JHF, Kester MGD, de Ru AH, van Veelen PA, Willemze R, . Sequence dependent efficiency of cross-presentation in MHC class I requires rational design of long synthetic peptides for vaccination or ex vivo activation. [Abstract] Blood. 2008;112: 1330–1.
   Google Scholar
• Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, Renter MJ, . Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad SciUSA. 1999;96: 10326–31.
   PubMed Web of Science ®Google Scholar
• Groothuis TA, Neefjes J. The many roads to cross-presentation. J Exp Med. 2005;202: 1313–18.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hong H, Li D, Ma S, Di Y, Stolen A, . Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. J Biol Chem. 2009;284: 9184–91.
   PubMed Web of Science ®Google Scholar